The Human Variable 

Remission in ME/CFS is often described as spontaneous, yet nothing about it is random. The illusion of rarity comes from measurement bias. We record symptoms, not trajectory. When patient data is plotted longitudinally rather than episodically, a clear pattern emerges. Remission occurs when the body’s internal feedback systems, immune, autonomic, and metabolic, temporarily synchronize

By October 2025, CYNAERA’s federal-scale models identified between $1.05 trillion and $3.45 trillion in potential annual savings for the United States through modular frameworks that stabilize health, accelerate remission, and optimize budgetary flow across SSA, CMS, VA, and FEMA

FEMA’s flood plans overlook infection-associated chronic conditions now affecting one-quarter of U.S. adults. This CYNAERA white paper introduces biologic disaster modeling using US-CCUC™, ESA™, VitalGuard™, and MoldX™ to forecast medical surges from mold, heat, and power loss. Applying these systems could prevent 70 percent of non-trauma ER visits and save $7.4 billion annually in federal costs.

Here I apply CYNAERA’s analytical framework to the unlikely case of a consumer snack, Frito-Lay’s Baked Lay’s, as an emergent functional-nutrition platform for dysautonomia and MCAS patients. Using CYNAERA’s prevalence modeling (US-CCUC™, S³™, Pathos™, SymCas™, BRAGS™) and global market-behavior analytics, I examine how a legacy brand could reposition a common product into a precision-nutrition solution. A $3 billion opportunity in plain sight.

Traditional medicine isolates diagnoses by organ or specialty. CYNAERA’s terrain logic views the body as an interdependent system where immune, endocrine, and autonomic signals co-determine stability. The Playbook applies three key insights from the Primary Chronic Trigger (PCT) Blueprint. Chronic illness begins with temporal ignition, an event that tips an unstable terrain. Chronicity persists when recovery conditions (RC) remain incomplete.

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

Infection-associated chronic conditions (IACCs) describe a single clinical terrain that appears under many labels—Long COVID, ME/CFS, POTS, MCAS, hEDS overlap, and post-infectious states following EBV, H1N1, Lyme, and Ebola. Triggers differ; downstream biology converges. Across cohorts, patients show immune dysregulation, autonomic instability, mitochondrial hypometabolism, mast-cell mediator sensitivity, connective-tissue fragility, and chronic neuroinflammation.

The Socioeconomic Phenotype Index (SPI™) represents a paradigm shift in how health science conceptualizes the role of socioeconomic status. For decades, poverty, access barriers, and discrimination have been categorized as “social determinants of health” (SDOH). While this framing acknowledges their impact, it relegates them to the periphery of medical science. SPI™ reframes these determinants as phenotypes — measurable biological terrains that directly influence disease o

Bioadaptive Systems Therapeutics™ (BST) is a new discipline of medicine that engineers remission by recalibrating fragile biological systems across immune, autonomic, mitochondrial, connective, hormonal, and environmental domains. Unlike traditional medicine, which classifies disease onset and treats within rigid silos, BST is phase-aware, terrain-first, and subtype-specific.

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

This white paper argues that MCS and MCAS are vantage points on a shared hypersensitivity terrain, proposing a new classification, Multi-Chemical and Environmental Hypersensitivity Disorders (MCEHD), that unites them, honors patient ingenuity, and formalizes my frameworks.